SeaSpine Expands Ventura™ NanoMetalene® Implant Offering to Accommodate Larger Range of Posterior Procedures
January 31 2018 - 7:00AM
SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical
technology company focused on surgical solutions for the treatment
of spinal disorders, today announced the portfolio expansion of the
Ventura™ NanoMetalene® posterior interbody device. Ventura
NanoMetalene, which has been commercially available since 2015, has
expanded its size offerings to accommodate a larger range of
posterior procedures and a wider variety of patient anatomies.
These new sizes include additional lengths and oblique placement
options with sagittally oriented lordosis.
The Ventura interbody devices feature proprietary NanoMetalene
surface technology. NanoMetalene describes a sub-micron layer
of commercially pure titanium molecularly bonded to a PEEK implant
using a high-energy, low-temperature process referred to as atomic
fusion deposition. It is designed to provide implants a
bone-friendly titanium surface on endplates and throughout graft
apertures, while retaining the benefits associated with traditional
PEEK implants, such as biocompatibility, a modulus of elasticity
similar to bone, and excellent radiographic visibility for
post-operative imaging.
Ali Chahlavi, MD, a neurosurgeon practicing in Jacksonville, FL
and an early adopter of NanoMetalene, commented, “NanoMetalene has
been an integral part of my fusion procedures. These implants
deliver the same surface characteristics of titanium while
maintaining PEEK’s radiolucency for clear assessment of fusion
post-operatively, which has not always been my experience with a
full titanium device.” With respect to the new lordotic options, he
said, “the additional lordosis will improve my ability to restore
better natural alignment to my patients.”
SeaSpine’s entire portfolio of posterior lumbar NanoMetalene
interbody devices is cleared for use with both autograft and
allograft. Having the additional indication allows surgeons more
bone grafting options, including using Ventura NanoMetalene with
SeaSpine’s new line of allograft demineralized bone fiber
products.
“NanoMetalene is a differentiated product in a market that has
become increasingly competitive,” stated Troy Woolley, Vice
President of Marketing. “The expansion of this technology coupled
with our advanced orthobiologics demonstrates our commitment to
provide complementary, cost-effective procedural solutions to
surgeons, hospitals and patients.”
About SeaSpine SeaSpine
(www.seaspine.com) is a global medical technology company focused
on the design, development and commercialization of surgical
solutions for the treatment of patients suffering from spinal
disorders. SeaSpine has a comprehensive portfolio of orthobiologics
and spinal implants solutions to meet the varying combinations of
products that neurosurgeons and orthopedic spine surgeons need to
perform fusion procedures on the lumbar, thoracic and cervical
spine. SeaSpine’s orthobiologics products consist of a broad range
of advanced and traditional bone graft substitutes that are
designed to improve bone fusion rates following a wide range of
orthopedic surgeries, including spine, hip, and extremities
procedures. SeaSpine’s spinal implants portfolio consists of an
extensive line of products to facilitate spinal fusion in minimally
invasive surgery (MIS), complex spine, deformity and degenerative
procedures. Expertise in both orthobiologic sciences and spinal
implants product development allows SeaSpine to offer its surgeon
customers a differentiated portfolio and a complete solution to
meet their fusion requirements. SeaSpine currently markets its
products in the United States and in over 30 countries
worldwide.
Forward-Looking
StatementsSeaSpine cautions you that statements included
in this news release that are not a description of historical facts
are forward-looking statements that are based on the Company's
current expectations and assumptions. Such forward-looking
statements may include, but are not limited to, statements relating
to: the design and other benefits of the Ventura NanoMetalene
portfolio; its ability to restore better natural alignment to
patients; and the ability of the Ventura NanoMetalene product to
provide complementary, cost-effective procedural solutions to
surgeons, hospitals and patients. Among the factors that
could cause or contribute to material differences between the
Company’s actual results and the expectations indicated by the
forward-looking statements are risks and uncertainties that
include, but are not limited to: the ability of the expanded
Ventura NanoMetalene portfolio to perform as designed and intended
and to meet the clinical needs of surgeons and patients; the
limited clinical experience supporting the commercial launch of new
products and the risk that such products may require substantial
additional development activities, which could introduce unexpected
expense and delay; the lack of long-term clinical data supporting
the safety and efficacy of the Company’s products; and other risks
and uncertainties more fully described in the Company’s news
releases and periodic filings with the Securities and Exchange
Commission. The Company’s public filings with the Securities and
Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. SeaSpine
does not intend to revise or update any forward-looking statement
set forth in this news release to reflect events or circumstances
arising after the date hereof, except as may be required by
law.
Investor Relations Contact Lynn Pieper (415) 937-5402
ir@seaspine.com
SeaSpine (NASDAQ:SPNE)
Historical Stock Chart
From Apr 2024 to May 2024
SeaSpine (NASDAQ:SPNE)
Historical Stock Chart
From May 2023 to May 2024